Celcuity (CELC) Misses Q2 EPS by 6c

Go back to Celcuity (CELC) Misses Q2 EPS by 6c

Celcuity Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Updates

August 10, 2023 4:04 PM EDT

Phase 3 VIKTORIA-1 clinical trial is now recruiting patients at nearly 200 sites in 20 countriesPresented updated results from Phase 1b study of gedatolisib in treatment-naïve advanced breast cancer at the ESMO Breast Cancer Annual CongressMedian progression free survival (PFS) was 48.6 months in treatment-naïve patients with HR+/HER2- advanced breast cancer who were treated with gedatolisib in combination with palbociclib and letrozoleManagement to host webcast and conference call today, August 10, 2023, at 4:30 p.m. ET

MINNEAPOLIS, Aug.... More